TCT 458: Invasive versus Conservative Management in Patients with Asymptomatic Ischemia: Insights from the ISCHEMIA Trial

<p>Within the prior 24 months, I have had a financial relationship with a company producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients: </p><ul><li>Grant Support/Research Contract - Abbott</li><li>Consultant Fee/Honoraria/Speaker's Bureau - Pfizer; Biotronik; Boston Scientific Corporation; Inari Medical</li></ul>